Lpath Sets Investor Update Conference Call for Thursday, January 3, 2013 at 4:30 p.m. ET SAN DIEGO, CA -- (Marketwire) -- 12/26/12 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, will hold a conference call on Thursday, January 3, 2013 at 4:30 p.m. Eastern time to provide an update on its Nexus Phase 2 trial for iSONEP(TM), an ocular drug candidate, as well as outline the company's 2013 objectives. Lpath President and CEO Scott Pancoast will host the presentation, followed by a question-and-answer period. Date: Thursday, January 3, 2013 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Dial-in number: 1-877-941-1427 International dial-in: 1-480-629-9664 Conference ID number: 4584568 Webcast and replay: http://public.viavid.com/index.php?id=102952 Please call the conference telephone number 5-10 minutes prior to the start time. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860. A telephone replay of the call will be available after 7:30 p.m. Eastern time on the same day and until February 3, 2013. Toll-free replay number: 1-877-870-5176 International replay number: 1-858-384-5517 Replay pin number: 4584568 About Lpath San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath's ImmuneY2(TM) drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates: iSONEP(TM) is currently in a Phase 2 trial for wet AMD; ASONEP(TM) is scheduled to begin a Phase 2a trial in Renal Cell Carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in neuropathic pain, neurotrauma, and other diseases. For more information, visit www.Lpath.com. Lpath, Inc. Scott R. Pancoast President & CEO (858) 926-3200 spancoast@Lpath.com Lpath Investor Relations Liolios Group, Inc. (949) 574-3860 Ron Both: email@example.com Geoffrey Plank: firstname.lastname@example.org LPTN@liolios.com
Lpath Sets Investor Update Conference Call for Thursday,
Press spacebar to pause and continue. Press esc to stop.